Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: The OVERCOME trial (prevention of left ventricular dysfunction with enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of malignant hEmopathies)

Journal of the American College of Cardiology

Volumn 61, Issue 23, 2013, Pages 2355-2362

  Bosch, Xavier ^a   Rovira, Montserrat ^a   Sitges, Marta ^a   Domènech, Ariadna ^a   Ortiz Pérez, José T ^a   De Caralt, Teresa M ^b   Morales Ruiz, Manuel ^a   Perea, Rosario J ^b   Monzó, Mariano ^a,c   Esteve, Jordi ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b Physiology Section   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

cardiac toxicity; carvedilol; chemotherapy; enalapril; left ventricular dysfunction; prevention

Indexed keywords

ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; TROPONIN I;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BRADYCARDIA; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL PROTOCOL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPOTENSION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINUS RHYTHM; SYSTOLIC BLOOD PRESSURE;

ADULT; ANTINEOPLASTIC AGENTS; CARBAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY, DOPPLER; ENALAPRIL; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROPANOLAMINES; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84878731843     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.02.072     Document Type: Article

References (22)

1. L.B. Travis, C.S. Rabkin, and L. Morris Brown Cancer survivorship: genetic susceptibility and second primary cancers: research strategies and recommendations J Natl Cancer Inst 98 2006 15 25 (Pubitemid 43057089)
2. E.T.H. Yeh, A.T. Tong, and D.J. Lenihan Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management Circulation 109 2004 3122 3131
3. N. Schmitz, M. Kloess, and M. Reiser Four versus six courses of dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (MegaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma Cancer 106 2006 136 145 (Pubitemid 43032558)
4. T. Kuittinen, E. Jantunen, and E. Vanninnen Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation Eur J Haematol 77 2006 120 127
5. T. Chung, W.-C. Lim, R. Sy, I. Cunningham, J. Trotman, and L. Kritharides Subacute cardiac toxicity following autologous haematopoietic stem cell transplantation in patients with normal cardiac function Heart 94 2008 911 918 (Pubitemid 351914704)
6. S.A. Hunt, W.T. Abraham, and M.H. Chin 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 53 2009 1343 1382
7. D. Cardinale, A. Colombo, and G. Lamantia Anthracycline-induced cardiomyopathy. Clinical relevance and response to pharmacologic therapy J Am Coll Cardiol 55 2010 213 220
8. G. Sacco, M. Bigioni, S. Evangelista, C. Goso, S. Manzini, and C.A. Maggi Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat Eur J Pharmacol 414 2001 71 78 (Pubitemid 32174877)
9. M. Vaynblat, H.R. Shah, and D. Bhaskaran Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin Eur J Heart Fail 4 2002 583 586 (Pubitemid 35278509)
10. D. Cardinale, A. Colombo, and M.T. Sandri Prevention of high-risk chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition Circulation 114 2006 2474 2481 (Pubitemid 44901520)
11. D.L. Santos, A.J. Moreno, R.L. Leino, M.K. Froberg, and K.B. Wallace Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy Toxicol Appl Pharmacol 185 2002 218 227 (Pubitemid 36062795)
12. P. Spallarossa, S. Garibaldi, and P. Altieri Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro J Mol Cell Cardiol 37 2004 837 846 (Pubitemid 39222076)
13. N. Kalay, E. Basar, and I. Ozdogru Protective effects of carvedilol against anthracycline-induced cardiomyopathy J Am Coll Cardiol 48 2006 2258 2262 (Pubitemid 44855419)
14. N.A. El-Shitany, O.A. Tolba, M.R. El-Shanshory, and E.E. El-Hawary Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia J Card Fail 18 2012 607 613
15. P. Vantrimpont, J.L. Rouleau, and C.C. Wun Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE investigators J Am Coll Cardiol 29 1997 229 236 (Pubitemid 27059948)
16. X. Bosch, J. Esteve, and M. Sitges Prevention of chemotherapy-induced left ventricular dysfunction with enalapril and carvedilol: rationale and design of the OVERCOME trial J Card Fail 17 2011 643 648
17. S.F. Nagueh, C.P. Appleton, and T.C. Gillebert Recommendations for the evaluation of left ventricular diastolic function by echocardiography J Am Soc Echocardiogr 22 2009 107 133
18. J.H. Silber, A. Cnaan, and B.J. Clark Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines J Clin Oncol 22 2004 820 828 (Pubitemid 41103593)
19. C. Huang, X. Zhang, and J.M. Ramil Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice Circulation 121 2010 675 683
20. J.R. Carver, C.L. Shapiro, and A. Ng American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects J Clin Oncol 25 2007 3991 4008 (Pubitemid 47477279)
21. S.C. Burjonroppa, A.T. Tong, L.C. Xiao, M.M. Johnson, S.W. Yusuf, and D.J. Lenihan Cancer patients with markedly elevated B-type natriuretic peptide may not have volume overload Am J Clin Oncol 30 2007 287 293 (Pubitemid 46884150)
22. T. Furian, C. Aguiar, and K. Prado Ventricular dysfunction and dilation in severe sepsis and septic shock: relation to endothelial function and mortality J Crit Care 27 2012 319 e9-15